BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Epilepsy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Epilepsy\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06063850-8963@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AMT-260: Phase 1/2 readout est. (NCT06063850)
DESCRIPTION:AMT-260\, phase 1/2\, Epilepsy.\nStudy: AMT-260 Gene Therapy St
 udy in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy\nEs
 timated primary completion: 30 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amt-260#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06063850
URL:https://assetmemo.bio/drug/amt-260#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06443463-8940@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opakalim: Phase 2 readout est. (NCT06443463)
DESCRIPTION:Opakalim\, phase 2\, Epilepsy.\nStudy: Long-term Safety and Tol
 erability of BHV-7000\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/opakalim#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06443463
URL:https://assetmemo.bio/drug/opakalim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132893-8940@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Opakalim: Phase 2/3 readout est. (NCT06132893)
DESCRIPTION:Opakalim\, phase 2/3\, Epilepsy.\nStudy: A Study to Determine i
 f BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epi
 lepsy\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/opakalim#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06132893
URL:https://assetmemo.bio/drug/opakalim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010471-8983@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relutrigine: Phase 3 readout est. (NCT07010471)
DESCRIPTION:Relutrigine\, phase 3\, Epilepsy.\nStudy: A Clinical Trial for 
 Participants With DEE to Assess Efficacy\, Safety\, Tolerability\, and PK 
 of Relutrigine\nEstimated primary completion: December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/relutrigine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07010471
URL:https://assetmemo.bio/drug/relutrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019922-8868@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elsunersen: Phase 3 readout est. (NCT07019922)
DESCRIPTION:Elsunersen\, phase 3\, Epilepsy.\nStudy: A Clinical Trial of El
 sunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elsunersen#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07019922
URL:https://assetmemo.bio/drug/elsunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03474770-8879@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Huperzine A (SPN-817): Phase 1/2 readout est. (NCT03474770)
DESCRIPTION:Huperzine A (SPN-817)\, phase 1/2\, Epilepsy.\nStudy: BIS-001-E
 R for the Treatment of Adult Focal Impaired Awareness Seizures\nEstimated 
 primary completion: 30 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/huperzine-a-spn-817#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03474770
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04289467-8885@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fintepla (Fenfluramine): Phase 2 readout est. (NCT04289467)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 2\, Epilepsy.\nStudy: Treatment
  of Refractory Infantile Spasms With Fenfluramine\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fenfluramine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04289467
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660394-8867@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06660394)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Phase 3\, Placebo-C
 ontrolled Study to Investigate LP352 in Children and Adults With Dravet Sy
 ndrome (DS)\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06660394
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600736-8907@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:ABS-1230: Phase 2 readout est. (NCT07600736)
DESCRIPTION:ABS-1230\, phase 2\, Epilepsy.\nStudy: A Study to Investigate t
 he Safety\, Tolerability\, Pharmacokinetics\, and Clinical Activity of ABS
 -1230 in Pediatric and Young Adult Participants With KCNT1-related Epileps
 y\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abs-1230#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07600736
URL:https://assetmemo.bio/drug/abs-1230#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505004-8949@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07505004)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Randomized Clinical 
 Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Fo
 cal Seizures\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/vormatrigine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07505004
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590896-8851@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xcopri (Cenobamate): Phase 2 readout est. (NCT06590896)
DESCRIPTION:Xcopri (Cenobamate)\, phase 2\, Epilepsy.\nStudy: Safety of Cen
 obamate in Japanese Subjects With Partial Onset Seizures\nEstimated primar
 y completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cenobamate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06590896
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579573-8851@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT06579573)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: ONO-2017 Stud
 y Japanese Patients With Primary Generalized Tonic Clonic Seizures.\nEstim
 ated primary completion: 31 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cenobamate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06579573
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05219617-8747@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Carisbamate: Phase 3 readout est. (NCT05219617)
DESCRIPTION:Carisbamate\, phase 3\, Epilepsy.\nStudy: Investigate Efficacy 
 and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated 
 With LGS in Children and Adults\nEstimated primary completion: February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carisbamate#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05219617
URL:https://assetmemo.bio/drug/carisbamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02962414-9023@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Everolimus: Phase 3 readout est. (NCT02962414)
DESCRIPTION:Everolimus\, phase 3\, Epilepsy.\nStudy: Roll-over Study to Col
 lect and Assess Long-term Safety of Everolimus in Patients With TSC and Re
 fractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and 
 Who Are Benefitting From Continued Treatment\nEstimated primary completion
 : 26 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 verolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02962414
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077904-8884@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05077904)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Efficacy and Safety of Staccato Alprazolam in Study Participants 12
  Years of Age and Older With Stereotypical Prolonged Seizures\nEstimated p
 rimary completion: 29 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05077904
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667142-819@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05667142)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Study to Evaluate X
 EN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/azetukalner#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05667142
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462770-8988@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Clemizole (EPX-100): Phase 3 readout est. (NCT04462770)
DESCRIPTION:Clemizole (EPX-100)\, phase 3\, Epilepsy.\nStudy: A Study of EP
 X-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/clemizole-epx-100#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04462770
URL:https://assetmemo.bio/drug/clemizole-epx-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015141-1636@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT04015141)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: A Study to E
 valuate Efficacy and Safety of Perampanel Administered as an Adjunctive Th
 erapy in Pediatric Participants With Childhood Epilepsy\nEstimated primary
  completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04015141
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401707-1636@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT06401707)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: PeRampanel f
 Or Status ePilEpticus pRophylaxis Post-cardiac Arrest\nEstimated primary c
 ompletion: 20 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06401707
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06798896-8879@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT06798896)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: RENAISSANCE
  2: SPN-817 Phase 2\, Double-Blind\, Placebo-Controlled Study in Adults Wi
 th Focal Onset Seizures\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/huperzine-a-spn-817#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06798896
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612775-8958@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CB03-154: Phase 2 readout est. (NCT06612775)
DESCRIPTION:CB03-154\, phase 2\, Epilepsy.\nStudy: A Study to Evaluate the 
 Safety\, Tolerability\, and Efficacy of CB03-154 in Adult Patients With Fo
 cal Epilepsy\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cb03-154#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06612775
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680322-8865@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:AV078: Phase 2 readout est. (NCT07680322)
DESCRIPTION:AV078\, phase 2\, Epilepsy.\nStudy: Safety and Efficacy of AV07
 8 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epileps
 y (RESTOR-1)\nEstimated primary completion: 1 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/av078#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07680322
URL:https://assetmemo.bio/drug/av078#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064878-8885@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271108
DTEND;VALUE=DATE:20271109
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT05064878)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Epilepsy.\nStudy: A Phase 3
  Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 
 Deficiency Disorder.\nEstimated primary completion: 8 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fenfluramine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05064878
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908226-8867@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Bexicaserin: Phase 3 readout est. (NCT06908226)
DESCRIPTION:Bexicaserin\, phase 3\, Epilepsy.\nStudy: A Study to Investigat
 e LP352 in Children and Adults With Developmental and Epileptic Encephalop
 athy (DEE)\nEstimated primary completion: 11 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bexicaserin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06908226
URL:https://assetmemo.bio/drug/bexicaserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141329-8879@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT07141329)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: SPN-817 Ope
 n-Label Extension Study in Adults With Focal Onset Seizures\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/huperzine-a-spn-817#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07141329
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05518578-8879@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Huperzine A (SPN-817): Phase 2 readout est. (NCT05518578)
DESCRIPTION:Huperzine A (SPN-817)\, phase 2\, Epilepsy.\nStudy: Safety and 
 Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant E
 pilepsy\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05518578
URL:https://assetmemo.bio/drug/huperzine-a-spn-817#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05716100-819@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05716100)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: A Randomized Study of
  XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)\nEstimated prima
 ry completion: January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azetukalner#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05716100
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219407-8911@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:RAP-219: Phase 2 readout est. (NCT07219407)
DESCRIPTION:RAP-219\, phase 2\, Epilepsy.\nStudy: A Long-term Study of the 
 Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rap-219#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07219407
URL:https://assetmemo.bio/drug/rap-219#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594158-8851@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT07594158)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: A Study to Ev
 aluate the Safety\, Efficacy\, and PK of ONO-2017 in Japanese Patients Wit
 h POS 2 to 17 Year Olds\nEstimated primary completion: 30 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cenobamate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07594158
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227857-8920@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:S230815: Phase 1/2 readout est. (NCT07227857)
DESCRIPTION:S230815\, phase 1/2\, Epilepsy.\nStudy: A First-in-human Study 
 of S230815 in Pediatric Participants With KCNT1-related Developmental and 
 Epileptic Encephalopathy\nEstimated primary completion: 15 April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/s230815#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227857
URL:https://assetmemo.bio/drug/s230815#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287163-8949@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07287163)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Clinical Trial of Vo
 rmatrigine in Adult Patients With Epilepsy\nEstimated primary completion: 
 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vormatri
 gine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07287163
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05419492-9007@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:ETX101: Phase 1/2 readout est. (NCT05419492)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-
 Positive Dravet Syndrome\nEstimated primary completion: June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/etx101#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05419492
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723963-8942@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Cannabidiol (JZP926): Phase 2/3 readout est. (NCT07723963)
DESCRIPTION:Cannabidiol (JZP926)\, phase 2/3\, Epilepsy.\nStudy: A Study to
  Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of J
 uvenile Myoclonic Epilepsy\nEstimated primary completion: 1 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-jzp926#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772396
 3
URL:https://assetmemo.bio/drug/cannabidiol-jzp926#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076617-8884@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05076617)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Safety and Tolerability of Staccato Alprazolam in Study Participant
 s 12 Years of Age and Older With Stereotypical Prolonged Seizures\nEstimat
 ed primary completion: 30 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05076617
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238868-8958@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:CB03-154: Phase 2 readout est. (NCT07238868)
DESCRIPTION:CB03-154\, phase 2\, Epilepsy.\nStudy: An Open-label Study to E
 valuate Safety\, Tolerability\, and Efficacy of CB03-154 in Subjects Diagn
 osed With Epilepsy\nEstimated primary completion: January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cb03-154#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07238868
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130786-7060@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Levetiracetam (Keppra): Phase 2 readout est. (NCT07130786)
DESCRIPTION:Levetiracetam (Keppra)\, phase 2\, Epilepsy.\nStudy: Prophylact
 ic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With
  Primary Motor Cortex Brain Metastases\nEstimated primary completion: Febr
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/levetirace
 tam-keppra#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07130786
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563881-8911@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:RAP-219: Phase 3 readout est. (NCT07563881)
DESCRIPTION:RAP-219\, phase 3\, Epilepsy.\nStudy: Study Evaluating the Effi
 cacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS
 -1\nEstimated primary completion: July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rap-219#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07563881
URL:https://assetmemo.bio/drug/rap-219#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594119-8911@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:RAP-219: Phase 3 readout est. (NCT07594119)
DESCRIPTION:RAP-219\, phase 3\, Epilepsy.\nStudy: Study Evaluating the Effi
 cacy and Safety of RAP-219 in Adult Participants With Focal Seizures\nEsti
 mated primary completion: July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rap-219#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07594119
URL:https://assetmemo.bio/drug/rap-219#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06315322-8844@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20291116
DTEND;VALUE=DATE:20291117
SUMMARY:Brivaracetam: Phase 3 readout est. (NCT06315322)
DESCRIPTION:Brivaracetam\, phase 3\, Epilepsy.\nStudy: A Study to Test the 
 Long-term Safety and Tolerability of Brivaracetam in Study Participants Wi
 th Childhood Absence Epilepsy or Juvenile Absence Epilepsy\nEstimated prim
 ary completion: 16 November 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/brivaracetam#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06315322
URL:https://assetmemo.bio/drug/brivaracetam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04715646-8844@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300708
DTEND;VALUE=DATE:20300709
SUMMARY:Brivaracetam: Phase 3 readout est. (NCT04715646)
DESCRIPTION:Brivaracetam\, phase 3\, Epilepsy.\nStudy: A Study to Test the 
 Safety and Tolerability of Brivaracetam in Children and Adolescents With S
 eizures\nEstimated primary completion: 8 July 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/brivaracetam#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04715646
URL:https://assetmemo.bio/drug/brivaracetam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112275-9007@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ETX101: Phase 1/2 readout est. (NCT06112275)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101\, an AAV9-Delivered Gene Therapy in
  Children With SCN1A-positive Dravet Syndrome (Australia Only)\nEstimated 
 primary completion: September 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/etx101#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06112275
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06283212-9007@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:ETX101: Phase 1/2 readout est. (NCT06283212)
DESCRIPTION:ETX101\, phase 1/2\, Epilepsy.\nStudy: A Clinical Study to Eval
 uate the Safety and Efficacy of ETX101\, an AAV9-Delivered Gene Therapy in
  Children With SCN1A-positive Dravet Syndrome\nEstimated primary completio
 n: October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etx1
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6283212
URL:https://assetmemo.bio/drug/etx101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531745-9008@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:ION337: Phase 1/2 readout est. (NCT07531745)
DESCRIPTION:ION337\, phase 1/2\, Epilepsy.\nStudy: ASCEND: Safety and Toler
 ability of ION337 for the Treatment of Dravet Syndrome\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ion337#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07531745
URL:https://assetmemo.bio/drug/ion337#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718817-819@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20330430
DTEND;VALUE=DATE:20330501
SUMMARY:Azetukalner: Phase 3 readout est. (NCT05718817)
DESCRIPTION:Azetukalner\, phase 3\, Epilepsy.\nStudy: An Open-label Study o
 f XEN1101 in Epilepsy\nEstimated primary completion: April 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/azetukalner#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05718817
URL:https://assetmemo.bio/drug/azetukalner#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
